Efficacy of Ripretinib

Ripretinib, as a broad-spectrum kinase inhibitor, can inhibit various gene mutations and improve the progression-free survival of patients with advanced gastrointestinal stromal tumors (GIST). It can effectively treat mutations that are resistant to chemotherapy with other kinase inhibitors such as imatinib (imatinib). Repetinib has a tendency to cause cardiac dysfunction and new primary cutaneous malignancies, and it is important to measure cardiac ejection fraction before and during treatment and to perform regular dermatological evaluations.

Protein kinases play important roles in cellular function, and their dysregulation can lead to carcinogenesis. Ripetinib inhibits protein kinases, including wild-type and mutant platelet-derived growth factor receptor A (PDGFRA) and KIT, that cause the majority of gastrointestinal stromal tumors (GIST). In vitro experiments show that repetinibcan inhibitPDGFRB, BRAF, VEGF and TIE2 genes.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.